Xponance Inc. Lowers Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Xponance Inc. reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 8.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,745 shares of the medical research company’s stock after selling 644 shares during the quarter. Xponance Inc.’s holdings in Charles River Laboratories International were worth $1,595,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. VisionPoint Advisory Group LLC grew its stake in shares of Charles River Laboratories International by 105.7% in the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after purchasing an additional 74 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Charles River Laboratories International in the third quarter worth about $37,000. Operose Advisors LLC bought a new stake in shares of Charles River Laboratories International in the third quarter worth about $42,000. Venturi Wealth Management LLC grew its stake in shares of Charles River Laboratories International by 74.7% in the third quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock worth $51,000 after purchasing an additional 112 shares during the last quarter. Finally, Provence Wealth Management Group bought a new stake in shares of Charles River Laboratories International in the third quarter worth about $57,000. 98.91% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on CRL shares. Robert W. Baird raised their target price on Charles River Laboratories International from $252.00 to $268.00 and gave the stock an “outperform” rating in a research note on Thursday, February 15th. TheStreet raised Charles River Laboratories International from a “c+” rating to a “b-” rating in a research report on Friday, March 1st. Citigroup lifted their price objective on Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research report on Thursday, February 15th. Guggenheim cut Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Finally, Evercore ISI lifted their price objective on Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a research report on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $253.23.

Charles River Laboratories International Price Performance

CRL stock opened at $239.98 on Wednesday. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00. The firm has a market capitalization of $12.36 billion, a price-to-earnings ratio of 26.06, a PEG ratio of 1.78 and a beta of 1.40. The firm has a 50 day moving average price of $254.27 and a 200-day moving average price of $222.23. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $991.25 million. During the same period in the previous year, the business earned $2.98 EPS. The firm’s revenue for the quarter was down 7.9% on a year-over-year basis. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Shannon M. Parisotto sold 5,882 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the transaction, the executive vice president now directly owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP William D. Barbo sold 4,050 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the sale, the vice president now owns 22,879 shares of the company’s stock, valued at $5,685,431.50. The disclosure for this sale can be found here. Insiders sold a total of 14,932 shares of company stock worth $3,693,663 in the last three months. Insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).